A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome.

Stiff P, Bayer R, Camarda M, Tan S, Dolan J, Potkul R, Loutfi S, Kinch L, Sosman J, Peace D
Gynecol Oncol. 1995 57 (3): 278-85

PMID: 7774830 · DOI:10.1006/gyno.1995.1143

MeSH Terms (18)

Adult Antineoplastic Combined Chemotherapy Protocols Bone Marrow Transplantation Carboplatin Cyclophosphamide Dose-Response Relationship, Drug Drug Administration Schedule Epithelium Female Humans Middle Aged Mitoxantrone Neoplasm Recurrence, Local Ovarian Neoplasms Prognosis Risk Factors Salvage Therapy Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: